Monitoring T Cell Responses to Improve Anti-PD-1 Therapy in Melanoma, Lung, and Other Advanced Cancers

What this Trial Is About

Researchers are studying the role of T cells in tracking disease status and response to anti-PD-1PD-L1 treatment in people with melanoma, lung, and other types of cancer. They aim to understand how levels of specific markers like Bim and soluble PD-L1 change during therapy and to identify why some patients respond to this treatment while others do not. This observational study focuses on patients with advanced or metastatic cancer stages. Participants provide blood samples regularly during the study to measure markers related to treatment response and resistance, including levels of NKG7 messenger RNA in CD8 T cells. Optional stool samples may be collected, and previously collected tissue samples can also be provided. Medical records are reviewed to gather additional information relevant to the study. Throughout the study, participants undergo blood draws at baseline, six weeks after starting therapy, and during each tumor assessment approximately every 9 to 12 weeks, including at confirmed disease progression. Researchers monitor these markers to evaluate treatment resistance and disease status. The study continues until December 2028, with ongoing assessments at scheduled intervals to understand treatment outcomes and mechanisms of resistance.

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types